Blueprint Medicines Corporation (BPMC) Dividend History

Company News

• Press Release: Sanofi completes acquisition of Blueprint Medicines

  Sanofi has completed its acquisition of Blueprint Medicines for $129 per share, adding a rare immunology medicine (Ayvakit/Ayvakyt) and promising pipeline focused on systemic mastocytosis to its portfolio.

  GlobeNewswire Inc.
• Deal Dispatch: TV Stations For Sale, This Buyer Wants Seconds On Pasta

  Several companies are up for sale, including TV stations, a health marketing agency, and a biotech firm. Post Holdings is acquiring a pasta brand, and Sanofi is buying Blueprint Medicines. Additionally, Alex Jones may have his personal assets sold due to bankruptcy.

  Benzinga

  Featured Companies: BKR
• Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand

  BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.

  Zacks Investment Research

  Featured Companies: BMRN IMVT KYMR LGND
• Biotech stocks set for a rebound in 2024, analysts say

  A more favorable interest-rate outlook, an uptick in deals, and innovations in key areas like cancer and immunology are setting up biotech for a brighter 2024, analysts say.

  MarketWatch

  Featured Companies: AMGN BMRN BMY IRON LLY MRUS PFE VKTX VRTX XBI
• Why Blueprint Medicines Stock Soared Today

  The precision-treatment company saw stronger-than-expected sales in its first full quarter following the launch of Ayvakit.

  The Motley Fool